Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

538
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

55
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

546
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
546
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

667
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
667
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.7K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein(a) Reflects Baseline Lipid Phenotype but Does Not Predict Long-Term Cardiometabolic Risk in Apparently Healthy Women.

Metabolites·2026
Same author

Shear-Dependent Agreement and Clinical Reclassification of Whole-Blood Viscosity Measurements: A Paired Comparison of Rheovis 2000A and Hemovister.

Diagnostics (Basel, Switzerland)·2026
Same author

Diagnostic and Prognostic Utility of Monocyte Cell Population Data in Emergency Department Patients with Suspected Sepsis.

Annals of laboratory medicine·2026
Same author

Multi-Marker Approach in Sepsis: A Clinical Role Beyond SOFA Score.

Medicina (Kaunas, Lithuania)·2026
Same author

Early Sepsis Detection in Adult Patients with Suspected Sepsis in an Emergency Setting: A Sequential Strategy of Monocyte Distribution Width and Presepsin.

Diagnostics (Basel, Switzerland)·2025
Same author

Performance Evaluation of the 2020 European Society of Cardiology 0-hour/1-hour Algorithm Using High-sensitivity Cardiac Troponin I for Non-ST-segment Elevation Acute Coronary Syndrome and Mortality Assessment Based on 1-year Real-world Data.

Annals of laboratory medicine·2025

Related Experiment Video

Updated: Mar 7, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.6K

The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice.

Hyun Suk Yang1, Seokhwan Yoon1, Mina Hur2

  • 1Department of Cardiovascular Medicine, Konkuk University Medical Center, 05030 Seoul, Republic of Korea.

Reviews in Cardiovascular Medicine
|March 6, 2026
PubMed
Summary
This summary is machine-generated.

Lipoprotein(a) [Lp(a)] is a key genetic cardiovascular risk factor affecting 1.5 billion people. This review highlights the gap in its clinical use and the emergence of new therapies to address this challenge.

Keywords:
RNA therapiesatherosclerotic cardiovascular diseasebiomarkersclinical practice guidelinesimplementation gaplipoprotein(a)mendelian randomization

More Related Videos

High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

523
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K

Related Experiment Videos

Last Updated: Mar 7, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.6K
High-Density Lipoprotein-Specific Phospholipid Efflux Assay
07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

523
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Pharmacology

Background:

  • Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor impacting 20% of the global population.
  • Despite strong evidence of its importance, clinical screening for Lp(a) remains below 1%, representing a significant implementation gap.
  • Persistent barriers include reimbursement issues, provider knowledge gaps, and laboratory standardization challenges.

Purpose of the Study:

  • To review the transformation of Lp(a) from an untreatable genetic risk factor to a promising therapeutic target.
  • To examine the evidence establishing Lp(a) as both a biomarker and a causal factor in cardiovascular disease.
  • To outline a practical management algorithm integrating current risk stratification with emerging therapies.

Main Methods:

  • Review of observational studies and Mendelian randomization to establish Lp(a)'s causal role in cardiovascular diseases.
  • Examination of novel RNA-targeted therapies demonstrating significant Lp(a) reduction.
  • Development of a management algorithm based on Lp(a) levels and emerging therapeutic interventions.

Main Results:

  • Elevated Lp(a) is causally linked to coronary heart disease, large-artery stroke, peripheral artery disease, and aortic stenosis.
  • Novel therapies achieve 80-95% reductions in Lp(a) levels.
  • Phase 3 cardiovascular outcome trials are ongoing to confirm clinical benefits of Lp(a) lowering.

Conclusions:

  • Lipoprotein(a) management is evolving from a genetic burden to a treatable condition through targeted therapies.
  • Closing the implementation gap for Lp(a) measurement and treatment is crucial for precision cardiovascular medicine.
  • Genetic insights and technological innovation are transforming the approach to cardiovascular risk management.